
    
      In an open, randomized clinical trial, the investigators compared seroconversion rates in 51
      predialysis patients with mild and moderate chronic renal failure using either 40 μg 4 doses
      or 20 μg 3 doses of Euvax B recombinant hepatitis B vaccine administered at 0, 1, 2, 6 and 0,
      1, 6 months respectively.
    
  